AI Pharmaceutical Technology Singularity and Industry Inflection Point

Text | Amino Observation

“Singularity” and “Inflection Point” together define the current era of AI-driven pharmaceutical development.

The former outlines the grand narrative of AI + life sciences— as technology continues to mature, the industry is experiencing continuous and explosive capability leaps; the latter is more aligned with industry realities, depicting the growth path that companies can truly implement after the arrival of technological singularity: not linear growth, but fission-like explosion.

This logic is further reinforced by external factors. For example, the capital markets are voting with real money, distinguishing “tech companies with revenue” from “revenue-generating tech companies.” AI pharmaceutical companies with genuine technological barriers and the ability to continuously create value are gaining definite capital premiums.

On March 9, as a typical example in the AI pharmaceutical sector, Yingxi Intelligent was officially included in the Hang Seng Composite Index and simultaneously entered the Stock Connect list. From listing to inclusion in the Stock Connect in just four months, this not only recognizes its market value and liquidity but also signifies tangible benefits:

On one hand, liquidity is further enhanced;

On the other hand, business potential is accelerating its release.

Through index inclusion and Stock Connect opening, the capital market provides liquidity and financial backing, with technological barriers and value creation forming the core fundamentals. The two form a positive cycle, accelerating the transformation into more certain long-term value and monetization capabilities for AI pharmaceutical companies.

Technological Singularity

As AI models, data, and computing power mature simultaneously, AI drug development is entering a critical point of continuous qualitative change.

The logic of improving R&D efficiency and success rates is becoming clearer. The NIH database report from February 2025 shows that by December 2023, 21 AI-developed drugs in Phase I trials had success rates of 80%–90%, significantly higher than the traditional method average of about 40%.

This qualitative change is more intuitively reflected in leading AI pharmaceutical companies.

For example, Yingxi Intelligent leverages its end-to-end Pharma.AI platform to compress the average cycle from project initiation to PCC to 12–18 months, far faster than the traditional 4.5 years. In actual R&D, performance may be even better. For instance, just eight months after strategic cooperation with Haisen Pharmaceuticals, Yingxi Intelligent efficiently nominated preclinical candidate compounds.

Today, AI has long ceased to be a question of “whether” in transforming the pharmaceutical industry; it’s about how strong its disruptive power is.

On one hand, the extension capability of New Modality is becoming stronger.

From industry development patterns, the bottleneck of single-drug development is increasingly apparent, and multi-modal drug development has become an important direction to break through druggability challenges and expand therapeutic boundaries. For AI pharmaceutical companies, exploring more diverse drug development pathways to overcome high-difficulty targets that traditional R&D struggles with is key to validating their technology and algorithms.

This is precisely the direction that leading AI pharmaceutical companies are breaking through. For example, Yingxi Intelligent is expanding generative AI capabilities into peptides, nanobodies, full-length antibodies, antibody-drug conjugates, and protein degradation chimeras through Pharma.AI’s generative engine Generative Biologics, with several substantive results already achieved.

Recently, Yingxi Intelligent announced that its oral GIPR antagonist ISM0676, designed by AI, was completed in just 14 months and has entered preclinical PCC stage; combined with semaglutide, it achieved up to 31.3% weight loss, with about 10.4% weight loss as a single agent. Both R&D speed and clinical effects have far exceeded industry expectations.

On the other hand, top AI pharmaceutical companies are upgrading from single-project R&D to full-chain industry empowerment.

In early 2026, Yingxi Intelligent launched the large model specialized training framework MMAI Gym, a highly symbolic event. MMAI Gym spans the entire R&D process. Specifically, the model is divided into two specialized tracks:

CSI Chemical Super Intelligence: focuses on reaction reasoning, retrosynthesis, molecular design, and property prediction;

BSI Biological/Clinical Super Intelligence: focuses on target discovery scoring, omics perception reasoning, and clinical trial success rate prediction.

Its purpose is simple: mainly to solve the common large model issues of “hallucination and unprofessionalism,” teaching general AI how to handle professional tasks such as pharmacokinetics (DMPK), toxicity endpoints (e.g., hERG, DILI risks), and molecular 3D structure-property relationship prediction, making results more accurate and trustworthy.

In simpler terms, it trains general large models (like GPT, Llama) from “jack of all trades” students to experts proficient in drug discovery. For example, after training with MMAI Gym, Alibaba’s Qwen model reduced its failure rate on industry-standard tests from 70% to below 5%, achieving a tenfold performance leap.

Imagine that after training with MMAI Gym, any model can achieve high-precision predictions— the era of truly democratized AI drug development is arriving.

Moreover, Yingxi Intelligent’s layout shows that AI’s high efficiency not only covers early R&D but also accelerates direct monetization in business development (BD) and other segments. Its Automated Partnering System, aimed at standardizing, streamlining, and intelligentizing industry BD collaborations, envisions “AI handles negotiations, humans make decisions,” breaking operational barriers to explosive innovation.

It’s clear that in the pharmaceutical industry, AI is transitioning from “a technological tool” to “an industry engine.”

Industry Inflection Point

Singularity arrives, and the inflection point follows.

For AI pharmaceutical companies, growth is not traditional linear but fission-like. After proof of concept from 0 to 1, the leap from 1 to 10, and then to 30 or even 100, can happen in the blink of an eye…

In practice, leading AI pharma companies have indeed mapped out high-growth paths following the arrival of technological singularity. Yingxi Intelligent is a highly representative case.

Currently, Yingxi Intelligent has clearly established two mature monetization paths, forming a solid foundation.

One is drug discovery and pipeline development, through licensing or co-developing high-value pipelines, earning upfront payments, milestone payments, and sales shares.

On the independent development front, the company has built an internal pipeline with over 28 preclinical candidates, covering high-value areas like fibrosis, oncology, immunology, and metabolism, with 12 already approved for clinical trials and multiple ongoing.

Yingxi’s molecules have clear clinical value and differentiation potential. The TNIK small molecule inhibitor Rentosertib (formerly ISM001-055) is a prime example. As the fastest progressing pipeline, it published positive Phase IIa results in Nature Medicine in June 2025, showing significant potential to reverse lung function deterioration and fill a therapeutic gap.

In terms of pipeline quantity and quality, the company exhibits characteristics of a mid-tier biopharma: broad coverage, reasonable stage distribution, and near-term monetization nodes, with strong sustainability.

Meanwhile, its AI strength and independent R&D capabilities make its monetization in BD and collaborations particularly robust. From Q1 2026 to now, upfront and milestone payments have reached about $45 million, close to last year’s total revenue ($55.8–$56.3 million).

The second is software solutions, generating steady subscription revenue through licensing Pharma.AI platform.

Currently, the company has established software platform collaborations with 13 of the top 20 global pharma companies, and has deepened its strategic cooperation with Qilu Pharmaceutical, moving from early platform licensing to over HKD 900 million in R&D collaborations, highly recognized by industry leaders.

The other side of reputation is real revenue. Public data shows that Yingxi Intelligent’s platform revenue has been rising since 2022, with a compound annual growth rate of 62.7% in 2024. In the first half of 2025 alone, recognized revenue exceeded 1.5 times that of 2022.

Supported by these two certain paths, the company already possesses strong explosive growth potential. But Yingxi Intelligent is not stopping; a second growth curve is accelerating and preparing to launch.

The deployment of the MMAI Gym training platform not only upgrades capabilities but also fundamentally innovates the business model. Through MMAI Gym, Yingxi Intelligent enables reverse empowerment, opening new high-margin markets for “scientific knowledge licensing” and “model deepening services.”

Indeed, Yingxi’s strategic layout is evident. On March 9, Yingxi Intelligent announced a strategic partnership with Liquid AI, a top AI company from MIT’s CSAIL, for MMAI Gym. They launched the lightweight foundational model LFM2-2.6B-MMAI, with 2.6 billion parameters, capable of covering over 200 specialized drug research tasks with local deployment, achieving industry-leading performance at low cost and high efficiency.

The first collaboration using MMAI Gym signals the official opening of new monetization channels.

Meanwhile, leveraging a unified technological foundation, the company is expanding its software solutions into non-pharmaceutical fields such as agriculture, advanced materials, and veterinary medicine, opening new growth horizons.

The emergence of the second growth curve not only brings performance increments but also confirms two key trends:

First, the risk resistance of AI pharmaceutical companies continues to strengthen as monetization models diversify; second, both visible and invisible strategic new opportunities will become future battlegrounds they can seize.

Clearly, under the dual layout of known and unknown, top AI pharmaceutical companies are showing full throttle in monetization, making the market more aware of their enormous future growth potential.

Accelerated Momentum

Under internal and external resonance, AI pharmaceutical companies are entering a phase of comprehensive acceleration.

Internally, monetization modes like platform technology licensing are in full swing, providing stable cash flow and vast real-world validation data; successful internal pipelines continuously feed back and iterate AI platform capabilities, making models more precise and efficient, ultimately creating a strong data flywheel. This flywheel further supports other businesses and expands monetization boundaries, injecting certainty into long-term high growth.

While internal certainty continues to rise, external conditions also bring multiple favorable factors, jointly pushing AI pharma companies to accelerate development.

Yingxi Intelligent’s quick inclusion in the Hong Kong Stock Connect exemplifies this. The capital market’s genuine investment recognizes its “tech-enabled revenue company” positioning and grants a certainty premium aligned with its technological barriers and commercialization ability.

Of course, being included in the Stock Connect is not only a capital event but also directly impacts industry development.

On one hand, the company’s brand and industry influence are significantly enhanced, further solidifying its position as “Hong Kong’s AI pharma leader,” attracting more high-quality industry chain collaborations and licensing opportunities;

On the other hand, increased capital and better financing environments directly support pipeline advancement, clinical investments, and commercialization, accelerating the transformation from technological value to business value.

Deeper still, this change continues to reinforce the positive cycle between AI pharma industry and capital: building core competitiveness through technological barriers, earning capital recognition via value creation, and reinvesting capital to strengthen technological barriers, forming a sustainable closed loop.

As this logic continues to be validated, the AI pharmaceutical industry will fully enter a new stage of industry realization and value realization.